Hurricane Energy (HUR)  shares rise 27.83% to 7.28p with stock gaining nearly 60% in 2022

Hurricane Energy told investors last week that it produced $59.5m from its latest oil shipment, in May 2022, which was priced at US$110 per barrel. The next cargo is due at the end of July.

Addressing shareholders at the time, the company said it had US$139mln of net free cash and after July’s bond repayment of US$78.5m it expects it will retain over US$75m - or US$90m if Brent remains above US$120 for the next cargo - to drive the business forward.

Hurricane Energy has a net free cash balance of $139 million as of 31 May 2022. It estimates an impact of around $5m from the new U.K. Energy Profits Levy up to the end of July 2022.

Poolbeg Pharma (POLB)   shares jump 24.44% to 5.6p following recent patent grants 

Last month, the London-based pharmaceutical company received patent grants from the US Patent & Trademark Office for its POLB 001 and POLB 002 molecules which it believes has marked an important step in the commercialisation of these infectious disease products.

In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. With its initial assets from Open Orphan, Poolbeg Pharma is targeting this growing infectious disease market.

Invinity Energy (IES)  shares jump 14.00% to 57p as it executes on US strategy 

In recent days, Invinity announced that it had expanded its presence in California with a new sales and corporate development office in San Francisco to underline the Company's commitment to growing its commercial, operational and corporate activities in the U.S.

Larry Zulch, Chief Executive Officer at Invinity Energy informed investors: "Invinity is well positioned to continue growing our leadership position in long-duration non-lithium energy storage in three of the world's most exciting markets - the UK, Australia and North America. 

As we expand on relationships and deliver marquee projects in these regions, we expect shareholder interest to follow. Our engagement with EAS underlines our commitment to commercial success in North America and building liquidity and long-term value for all of Invinity's existing and future shareholders with a significant presence in U.S. equity markets.

4D Pharma (DDDD)  shares fall 24.25% to 18.46p as stock sets new price lows

Shares in 4D Pharma reached a new 52-week low on Tuesday, dropping as low as 17.8p.

 Currently, 4d Pharma is leading the development of Live Biotherapeutic Products (LBPs), a novel class of drugs derived from the microbiome. Despite recent research on cancer drugs and other pioneering research work, market sentiments have remained relatively unaffected.